Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn’s disease: a systematic review and meta-analysis
Techniques in Coloproctology · 2024-12 · 28 (1)
DOI: 10.1007/s10151-024-02991-7 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Techniques in Coloproctology, online erschienen am 18.09.2024. Verfasst von W Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Surgery Division, Department of Surgery, St Paul's Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada. wlin5@providencehealth.bc.ca. Hauptthemen laut MEDLINE: Anastomosis, Surgical, Crohn Disease, Recurrence. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Kono-S anastomosis has gained increasing interest although evaluation of its impact on reducing Crohn's recurrence shows conflicting results. This study aimed to evaluate the short- and long-term outcomes for patients with Crohn's disease requiring surgery with Kono-S compared to conventional anastomosis. METHODS: A systematic review and meta-analysis included patients with Crohn's disease treated with bowel resection and Kono-S anastomosis reconstruction versus a comparator arm of conventional anastomosis technique. Recurrence outcomes examined were endoscopic recurrence rates, mean postoperative Rutgeerts score, surgical recurrence, clinical recurrence, and postoperative biologics use. Short-term postoperative outcomes include anastomotic leaks, surgical site infection, postoperative ileus, and mean operative time. RESULTS: A total of 873 studies were identified with 15 remaining after abstract review encompassing 1501 patients, 765 with Kono-S and 736 with conventional anastomosis. Recurrence was significantly lower in the Kono-S arm, with endoscopic recurrence rates of 41% vs 48% (RR 0.86, 95% CI 0.73-1.00, p = 0.05) and surgical recurrence rates of 2.7% vs 21.0% (RR 0.13, 95% CI 0.06-0.30, p < 0.001). There was a significantly lower anastomotic leak rate in the Kono-S arm when compared to conventional anastomosis, 1.7% vs 4.9% (RR 0.37, 95% CI 0.19-0.74, p = 0.005). Mean operative time was similar between both groups. CONCLUSIONS: Kono-S is a safe and feasible anastomotic technique with lower rates of endoscopic and surgical postoperative recurrence. While we await further trials to substantiate this benefit, Kono-S anastomosis should be considered as an important tool in the armamentarium of a surgeon in anastomotic construction to reduce recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Colorectal Surgery Division, Department of Surgery, St Paul's Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada. wlin5@providencehealth.bc.ca.
- Department of Colorectal Surgery, Singapore General Hospital, Singapore, Singapore. wlin5@providencehealth.bc.ca.
- Department of Surgery, Western University, London, ON, Canada.
- Colorectal Surgery Division, Department of Surgery, St Paul's Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada.
Zitieren
APA
Lin, W., Lemke, M., Ghuman, A., Phang, P. T., Brown, C. J., Raval, M. J., Clement, E. A., & Karimuddin, A. A. (2024). Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology, 28(1). https://doi.org/10.1007/s10151-024-02991-7
Vancouver
Lin W, Lemke M, Ghuman A, Phang PT, Brown CJ, Raval MJ, et al. Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology. 2024;28(1). doi:10.1007/s10151-024-02991-7
BibTeX
@article{Lin2024,
author = {Lin, W and Lemke, M and Ghuman, A and Phang, P T and Brown, C J and Raval, M J and Clement, E A and Karimuddin, A A},
title = {Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn’s disease: a systematic review and meta-analysis},
journal = {Techniques in Coloproctology},
year = {2024},
volume = {28},
number = {1},
doi = {10.1007/s10151-024-02991-7}
}
EUVIMED